ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibogaine hydrochloride

Also written as “Ibogaine Hydrochloride” and “DMX-1002”.

Its studies are mostly in Opioid-Related Disorders, led by 2 companies.

Drug pageIbogaine hydrochloride: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 19, 20262 company-led studies, 1 open or runningNext primary completion: Jan 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clive Michelsenits history only11 open or runningphase 2since Sep 19, 2026Sep 19, 2026Jan 31, 2029phase 2 · NCT07871877
Eli Lilly10 open or runningphase 2since May 13, 2021May 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2021First study: phase 2 study in Opioid-Related DisordersFirst studyNCT05029401 · 116 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05029401Opioid-Related Disorders · United Kingdom2CompletedJan 16, 2024116

How it is read

Names in the registry

  • “Ibogaine Hydrochloride”, 1 entry
  • “DMX-1002”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.